Get the Stockscreener App
15.78
1.68%
-0.27
Bausch Lomb Corp stock is traded at $15.78, with a volume of 560.31K.
It is down -1.68% in the last 24 hours and down -0.38% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$16.05
Open:
$16.06
24h Volume:
560.31K
Relative Volume:
1.36
Market Cap:
$5.62B
Revenue:
$5.10B
Net Income/Loss:
$-352.00M
P/E Ratio:
-15.49
EPS:
-1.0189
Net Cash Flow:
$-66.14M
1W Performance:
-4.88%
1M Performance:
-0.38%
6M Performance:
+0.00%
1Y Performance:
+23.86%
1-Day Range:
$15.62
$16.06
1-Week Range:
$15.62
$17.12
52-Week Range:
$10.45
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
15.78 | 5.72B | 5.10B | -352.00M | -66.14M | -1.0189 |
ISRG
Intuitive Surgical Inc
|
478.82 | 160.28B | 10.58B | 2.99B | 2.49B | 8.2405 |
BDX
Becton Dickinson Co
|
154.85 | 44.57B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
46.23 | 38.56B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.86 | 37.93B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
219.51 | 32.23B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
20 studies examine B vitamins for macular degeneration as new formula hits U.S. - Stock Titan
Bausch + Lomb targets net zero by 2050, trims lens plastic waste - Stock Titan
Why Bausch + Lomb (BLCO) Just Strengthened Something Beyond Earnings - Insider Monkey
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript - The Globe and Mail
Bausch + Lomb Corp stock (CA07174N1090): Why Google Discover changes matter more now - AD HOC NEWS
10 High Growth Canadian Stocks to Buy Now - Insider Monkey
Bausch + Lomb (NYSE:BLCO) Rating Increased to Buy at Wall Street Zen - MarketBeat
Bausch + Lomb Corporation - Baystreet.ca
Used contacts and lens packs add up: 725,000 pounds recycled - Stock Titan
Bausch & Lomb Legal Chief Sees Pay Dip To $3.6M In 2025 - Law360
Form 8-KCurrent report - ADVFN
Tudor Investment Corp ET AL Makes New Investment in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Opens with a 5.46% Gain, Outperforming S&P 500 - Markets Mojo
BLCO SEC FilingsBausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Bausch & Lomb Corp SEC Filing - Stock Titan
Bausch + Lomb (NYSE: BLCO) seeks approval to expand equity plan and elect board - Stock Titan
Bausch + Lomb Corporation Receives FDA 510(k) Clearance For Bi-Blade+ Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update - marketscreener.com
Bausch + Lomb Corp stock: Eye health innovation drives undervaluation debate - AD HOC NEWS
Bausch + Lomb receives FDA clearance for surgical device - Investing.com
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update - Business Wire
Bausch Lomb (NYSE:BLCO) Eye Health Story Gains Attention On Nyse Composite Today - Kalkine Media
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16.34 - 富途牛牛
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
A Look At Bausch + Lomb (NYSE:BLCO) Valuation As ASCRS Presentations Highlight Eye Health Portfolio - simplywall.st
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe - ChartMill
BLCO: Evercore ISI Group Adjusts Price Target While Maintaining Rating | BLCO Stock News - GuruFocus
Evercore Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $17 - 富途牛牛
Bausch + Lomb Corporation (BLCO) stock price, news, quote and history - Yahoo Finance Singapore
Dry eye and cataract data lead Bausch + Lomb's 45-study ASCRS lineup - Stock Titan
BLCO Stock Analysis: Bausch and Lomb Corp Common Shares 1.14% dip at 16.49 USD - Cổng thông tin điện tử tỉnh Lào Cai
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & SuppliesSpecialty Stocks - Yahoo! Finance Canada
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Should Positive ELIOS Glaucoma Trial Results Require Action From Bausch + Lomb (BLCO) Investors? - simplywall.st
Bausch + Lomb to webcast Q1 results and business update April 29 - Stock Titan
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29 - Yahoo Finance
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for I - AD HOC NEWS
Tudor Investment Corp ET AL Takes $2.25 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback - Yahoo Finance
Bausch And Lomb (NYSE:BLCO) Shares Draw Eyes Across Nyse Composite Today - Kalkine Media
3 Reasons BLCO is Risky and 1 Stock to Buy Instead - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - The Motley Fool
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $19 - 富途牛牛
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System - Intellectia AI
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma - BioSpace
Bausch + Lomb reports positive glaucoma trial results for ELIOS - Investing.com
Glaucoma laser left 82% of patients medication-free in U.S. trial - Stock Titan
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Market Shifts and Deb - AD HOC NEWS
RBC reiterates Bausch & Lomb stock rating on DED rival delay - Investing.com Australia
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):